Who is sponsoring NCT05163509?

NCT05163509 is sponsored by Sun Yat-sen University.

What drugs are being tested in NCT05163509?

Interventions in NCT05163509: Unity-based MR-Linac guided Radiotherapy.

What condition does NCT05163509 study?

NCT05163509 studies Mediastinal Tumor.

Is NCT05163509 still recruiting?

NCT05163509 is currently status unknown. Last updated 20 December 2021.

Last reviewed 2021-12-20 · How we verify

NCT05163509

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MR-linac Guided Adaptive Radiotherapy for Inoperable Mediastinal Tumor

Status unknown Phase 2 Last updated 20 December 2021

What this trial tests

Phase 2 trial testing Unity-based MR-Linac guided Radiotherapy in Mediastinal Tumor in 59 participants. Status unknown.

Timeline

1 October 2021

Primary endpoint
1 October 2023

1 October 2023

Quick facts

Lead sponsor	Sun Yat-sen University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	59
Start date	1 October 2021
Primary completion	1 October 2023
Estimated completion	1 October 2023
Sites	1 location across China

Drugs / interventions tested

Unity-based MR-Linac guided Radiotherapy

Conditions studied

Mediastinal Tumor — all drugs for Mediastinal Tumor →

Sponsor

Sun Yat-sen University

Who can join

Adults 18 to 75, any sex, with Mediastinal Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This Phase II study is to determine the efficacy and safety of MR-Linac Guided Radiotherapy in patients with inoperable mediastinal tumors.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Mediastinal Tumor

Currently open trials in the same condition.

NCT05682742 — Clinical Investigation of the da Vinci Surgical System · NA · active not recruiting
NCT05267496 — Oscillating Positive Expiratory Pressure Therapy for Patients With Thoracic Neoplasms Undergoing Chest Surgery · NA · active not recruiting

Other Sun Yat-sen University trials

Trials by the same sponsor.

NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05163509 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
Last refreshed: 20 December 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05163509.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing